AMLX
Price
$16.36
Change
+$0.08 (+0.49%)
Updated
Jun 23, 04:59 PM (EDT)
Capitalization
1.82B
44 days until earnings call
Intraday BUY SELL Signals
ANVS
Price
$1.74
Change
-$0.03 (-1.69%)
Updated
Jun 23, 04:59 PM (EDT)
Capitalization
74.02M
56 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMLX vs ANVS

AMLX vs ANVS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
AMLX vs. ANVS commentary
Jun 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMLX is a Buy and ANVS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 24, 2026
Stock price -- (AMLX: $16.28 vs. ANVS: $1.77)
Brand notoriety: AMLX and ANVS are both not notable
AMLX represents the Pharmaceuticals: Generic, while ANVS is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: AMLX: 114% vs. ANVS: 71%
Market capitalization -- AMLX: $1.82B vs. ANVS: $75.3M
AMLX [@Pharmaceuticals: Generic] is valued at $1.82B. ANVS’s [@Biotechnology] market capitalization is $75.3M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $118.47B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.92B. The average market capitalization across the [@Biotechnology] industry is $2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMLX’s FA Score shows that 0 FA rating(s) are green whileANVS’s FA Score has 0 green FA rating(s).

  • AMLX’s FA Score: 0 green, 5 red.
  • ANVS’s FA Score: 0 green, 5 red.
According to our system of comparison, AMLX is a better buy in the long-term than ANVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMLX’s TA Score shows that 5 TA indicator(s) are bullish while ANVS’s TA Score has 2 bullish TA indicator(s).

  • AMLX’s TA Score: 5 bullish, 4 bearish.
  • ANVS’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, AMLX is a better buy in the short-term than ANVS.

Price Growth

AMLX (@Pharmaceuticals: Generic) experienced а +7.18% price change this week, while ANVS (@Biotechnology) price change was -0.56% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.70%. For the same industry, the average monthly price growth was +0.08%, and the average quarterly price growth was +8.31%.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.89%. For the same industry, the average monthly price growth was +2.09%, and the average quarterly price growth was +1952.22%.

Reported Earning Dates

AMLX is expected to report earnings on Aug 06, 2026.

ANVS is expected to report earnings on Aug 18, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.70% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (+5.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMLX($1.82B) has a higher market cap than ANVS($74M). AMLX YTD gains are higher at: 34.768 vs. ANVS (-48.844). ANVS has higher annual earnings (EBITDA): -41.42M vs. AMLX (-158.8M). AMLX has more cash in the bank: 280M vs. ANVS (14.2M). AMLX (0) and ANVS (0) have equivalent revenues.
AMLXANVSAMLX / ANVS
Capitalization1.82B74M2,458%
EBITDA-158.8M-41.42M383%
Gain YTD34.768-48.844-71%
P/E Ratio2.69N/A-
Revenue00-
Total Cash280M14.2M1,972%
Total Debt5.63MN/A-
FUNDAMENTALS RATINGS
ANVS: Fundamental Ratings
ANVS
OUTLOOK RATING
1..100
14
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
85
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AMLXANVS
RSI
ODDS (%)
Bearish Trend 2 days ago
84%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 6 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
79%
Declines
ODDS (%)
Bearish Trend 16 days ago
82%
Bearish Trend 14 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
AMLX
Daily Signal:
Gain/Loss:
ANVS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MCSCX13.820.07
+0.51%
M3Sixty Small Cap Growth
RYVLX923.62N/A
N/A
Rydex NASDAQ-100® 2x Strategy A
IBSAX6.96N/A
N/A
VY® Baron Growth A
CGWRX78.09N/A
N/A
Columbia Cornerstone Growth R
ESGNX21.67-0.10
-0.46%
Mirova Global Megatrends N

ANVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ANVS has been loosely correlated with ADXN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ANVS jumps, then ADXN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ANVS
1D Price
Change %
ANVS100%
+1.14%
ADXN - ANVS
43%
Loosely correlated
+5.16%
MDGL - ANVS
36%
Loosely correlated
+1.59%
JAZZ - ANVS
35%
Loosely correlated
+0.56%
AMLX - ANVS
34%
Loosely correlated
+3.89%
CCXI - ANVS
34%
Loosely correlated
+0.63%
More